Cérivastatine
En pharmacologie, la cérivastatine (Baycol®, Lipobay®, Cholstat®, Staltor®) était un médicament synthétique de la classe des statines, qui était utilisé pour diminuer la cholestérolémie et prévenir les maladies cardiovasculaires. Il a été retiré du marché en 2001 à cause du taux élevé d'effets secondaires graves.
Texte anglais à traduire :
Cerivastatin was marketed by the pharmaceutical company Bayer A.G. in the late 1990s as a new synthetic statin, to compete with Pfizer's highly successful Lipitor®.
During post-marketing surveillance, 52 deaths were reported in patients using cerivastatin, mainly from rhabdomyolysis and its resultant renal failure. Risks were higher in patients using fibrates (mainly gemfibrozil/Lopid®) and in patients using the high (0.8 mg/day) dose of cerivastatin. Another 385 nonfatal cases of rhabdomyolysis were reported. This put the risk of this (rare) complication at 5-10 times that of the other statins.
In 2001, Bayer announced the voluntary withdrawal of the drug from the market.
| Cérivastatine | |
 | |
| Identification | |
|---|---|
| No CAS | |
| Code ATC | C10 |
| SMILES | |
| InChI | |
| Propriétés chimiques | |
| Formule brute | C26H34FNO5 [Isomères] |
| Masse molaire[1] | 459,5503 ± 0,0249 g/mol C 67,95 %, H 7,46 %, F 4,13 %, N 3,05 %, O 17,41 %, |
| Unités du SI et CNTP, sauf indication contraire. | |
Références
- (en) Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207. .
- (en) World Health Organization - Alert: Voluntary withdrawal of Cerivastatin – Reports of Rhabdomyolysis.
- Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.
